GlaxoSmithKline and OncoMed Pharmaceuticals form strategic alliance
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) and OncoMed Pharmaceuticals (OncoMed) today announced a worldwide strategic alliance to discover, develop and market novel antibody therapeutics to target cancer stem cells which are believed to play a key role in the establishment, metastasis and recurrence of cancer. The alliance with GSK will be conducted through its Center of Excellencefor External Drug Discovery (CEEDD).
Pivotal Phase III Data Show Superior Efficacy of Rivaroxaban over Enoxaparin
- Details
- Category: Bayer
The oral, once-daily, investigational anticoagulant rivaroxaban (Xarelto®) is significantly more effective than enoxaparin, the standard of care, in preventing venous thromboembolism (VTE) in patients undergoing total hip replacement surgery. Data from the RECORD1 study show a 70% relative risk reduction (RRR) for rivaroxaban in total VTE when compared with enoxaparin (p<0.001) and an 88% RRR (p<0.001) in major VTE.
GSK's continued commitment to fighting HIV/AIDS results in approval of new formulations
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) announced that it had gained approval from the European Commission for a new indication for use in children and infants of its HIV fixed-dose combination medicine, Combivir (lamivudine/3TC and Zidovudine/AZT). Previously, Combivir has only been prescribed for use in adults and children over 12 years of age, the shift to new weight based prescribing will allow Combivir to be used in much younger children.
Pfizer and Adolor Enter into Exclusive Worldwide Collaboration
- Details
- Category: Pfizer
Pfizer Inc (NYSE: PFE) and Adolor Corporation (Nasdaq: ADLR) announced today an exclusive worldwide collaboration to develop and commercialize novel compounds, ADL5859 and ADL5747, for the treatment of pain. Both compounds are proprietary Delta opioid receptor agonist candidates with the potential to treat a wide range of inflammatory, neuropathic and acute pain conditions.
Merz Group experiences successful 2006/07 financial year
- Details
- Category: Financial
Merz GmbH & Co. KGaA, based in Frankfurt am Main, was able to continue the dynamic growth of the previous years during their 2006/07 financial year (ending June 30th). Group revenue increased by 12.8% to 535.5 million Euros (previous year: 474.6 million Euros) due to new product introductions and internationally successful marketing and sales measures.
AstraZeneca Presents New Depression and Anxiety Results for SEROQUEL XRâ¢
- Details
- Category: AstraZeneca
The first data from the SEROQUEL XR™ (quetiapine fumarate) Extended Release clinical development programme in major depressive disorder (MDD) and generalised anxiety disorder (GAD) were presented at the 7th International Forum on Mood and Anxiety Disorders (IFMAD) in Budapest, AstraZeneca announced today.
Journal of the American Medical Association (JAMA) Publishes One-Year ACUITY Trial Results
- Details
- Category: Clinical Trials
The Journal of the American Medical Association (JAMA) today published one-year results of the ACUITY trial, which show that acute coronary syndrome (ACS) patients treated with Angiomax(R) (bivalirudin) alone had similar rates of ischemic clinical outcomes compared with a more complicated treatment regimen of heparin plus a glycoprotein IIb/IIIa inhibitor (GP IIb/IIIa).[1]
More Pharma News ...
- Novartis further strengthens biologics capabilities in expansion of MorphoSys collaboration
- Bayer Schering Pharma paves the way to the next important oral contraceptive milestone
- FDA Issues Approvable Letter for Nebivolol for the Treatment of Hypertension
- GlaxoSmithKline obtains exclusive US OTC marketing rights to Mevacor® from Merck & Co., Inc.
- The Magic Johnson Foundation and Abbott Expand Focus of 'Campaign to End Black AIDS'
- Forest Laboratories and Lundbeck announces positive results of Lexapro® phase III study
- World Aids Day Campaign to Shine a Light of Hope on the HIV/AIDS Epidemic in the United States